# CanadaBuys #WS5994329939

PHAC requirement for Oblitoxaximab injection to treat inhalation anthrax

**Posted:** November 17, 2026
**Respond By:** December 08, 2026
**Identifier:** WS5994329939
**NAICS:** 325414, 424210

PHAC is seeking Oblitoxaximab injection to treat inhalation anthrax.
- **Government buyer:** Public Services and Procurement Canada (PSPC), on behalf of the Public Health Agency of Canada (PHAC).
- **OEM/proposed supplier:** **Elusys Therapeutics, Inc.**
- **Product:** Oblitoxaximab injection, an antitoxin for inhalation anthrax; no part number or quantity is specified.
- **Notable requirement:** The notice cites exclusive rights as the basis for the proposed contract. Other suppliers may submit evidence of their capability to meet the requirement.
- **Services and performance period:** None specified.

### Description

Public Services and Procurement Canada proposes to negotiate a contract with Elusys Therapeutics, Inc. on behalf of the Public Health Agency of Canada. The procurement is for Oblitoxaximab injection, an antitoxin used to treat inhalation anthrax. This Advance Contract Award Notice allows other suppliers to submit a statement of capabilities by the closing date; if none meet the requirements, the contracting officer may proceed with the proposed award.

[View original listing](https://canadabuys.canada.ca/en/tender-opportunities/tender-notice/ws5994329939-doc5994436969)
